Safety and Efficacy of DSM 32444 in the Treatment of Acute Upper Respiratory Infection

To compare efficacy following multiple doses of the SPEROVID Nasal Spray for 10 days with those of the Neomycin Nasal Spray in Influenza Patients assessed by time to symptom resolution

Respiratory infection is the leading cause of disease burden worldwide, measured by years
 lost through death or disability. Of all respiratory infections, influenza is one of the most
 common illnesses the low middle income countries, and in Vietnam. It is directly responsible
 for 3-5 million cases of severe illnesses, and 600K deaths. According to the latest data
 published by World Health Organisation (WHO) , in 2020, Influenza and Pneumonia deaths in
 Viet Nam reached 27,836 or 4.06% of total deaths. It also ranks 6th in the leading causes of
 deaths in Vietnam. As with COVID-19, in Vietnam alone, there were in total 11.5 million cases
 causing nearly 45,000 deaths. Total hospitalized cases due to SARS-CoV-2 were not measurable,
 but they created unprecedented pressure on the country's health system.
 
 The most common treatment for influenza is antivirals and antibiotics. However, these regimes
 do have a lot of negative consequences on patients' health in the long term.
 
 Current concerns about antimicrobial resistance (AMR) have led to an urgent need for a
 nature-based next generation therapeutic approach that is safe, effective and helps in
 addressing the issues of AMR.
 
 This phase purpose is to evaluate the safety and efficacy of DSM 32444 in the treatment of
 influenza and acute upper respiratory infections.